SGMT — Sagimet Biosciences Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSmall CapNeutral

Annual balance sheet for Sagimet Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	68.7	56.7	32.3	94.9	151
Prepaid Expenses
Total Other Current Assets
Total Current Assets	68.7	58.7	32.8	96.6	153
Net Property, Plant And Equipment	0.194	0.342	0.212	0.073	0.077
Long Term Investments
Total Assets	69	59	33	96.7	160
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	1.91	2.44	5.28	5.65	4.45
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	1.98	2.67	5.36	5.65	4.45
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	67	56.4	27.7	91.1	156
Total Liabilities & Shareholders' Equity	69	59	33	96.7	160
Total Common Shares Outstanding
Total Preferred Shares Outstanding